Scleroderma drug trial shows up to 60% improvement
Drug Discovery World
NOVEMBER 30, 2023
Professor Dinesh Khanna, Frederick GL Huetwell Professor of Rheumatology and Director, Scleroderma Program at the University of Michigan said: “The mechanism of action for FT011 offers an important point of difference for the scleroderma research field as the upstream inhibition of inflammation and fibrosis may offer meaningful clinical outcomes.
59 
Let's personalize your content